Pharma News & Analysis
Monday, March 18, 2024
Madrigal Pharmaceuticals' Rezdiffra (resmetirom, THR-β agonist) becomes the first US FDA approved drug for the treatment of NASH (MASH)
›
Madrigal Pharmaceuticals' Rezdiffra ( resmetirom , THR-β agonist ) becomes the first US FDA approved drug for the treatment of NASH (...
Thursday, November 9, 2023
IMFINZI (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
›
Results from the EMERALD-1 Phase III trial have showcased positive high-level outcomes for AstraZeneca's IMFINZI (durvalumab) when combi...
Bristol Myers Squibb and Tempus enter into collaboration for AI approaches
›
Tempus, a prominent player in the realm of artificial intelligence and precision medicine, has unveiled a strategic and multi-year researc...
Tuesday, October 17, 2023
TAGRISSO Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
›
AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO (osimertinib) combined with chemotherapy has been accepted and gra...
Cimeio Therapeutics and University of Pennsylvania Collaborate on CD45 CAR T Cell Therapy for Blood and Bone Marrow Cancers
›
Cimeio Therapeutics, a key player in the field of innovative therapeutics, has made a significant announcement regarding a preclinical res...
›
Home
View web version